Teva Pharmaceuticals, the U.S. arm of Teva Pharmaceutical Industries Ltd. (TEVA), has released data aimed at enhancing clinical strategies for transitioning patients to UZEDY. UZEDY is an extended-release injectable suspension of risperidone, administered subcutaneously every one or two months, designed for treating schizophrenia in adults. This transition is from Perseris (RBP-7000), a once-monthly subcutaneous injection.
Schizophrenia is a complex condition, often necessitating a shift from oral medication or between various long-acting injectable options throughout a patient's treatment. The newly presented data deepen the understanding of optimal treatment strategies when switching to UZEDY from Perseris.
According to the company, recent findings indicate that transitioning to UZEDY four weeks after the last dose of the once-monthly RBP-7000 yields a similar pharmacokinetic (PK) profile based on relevant simulations, with comparable dosing identified.